SPRIM Global Investments

SPRIM Global Investments

SPRIM Global Investments extends from the SPRIM group, a consultancy founded at the intersection of health, innovation, and regulation. The investment arm formalizes what was already happening inside the advisory business: identifying and backing companies that address unmet medical needs. The firm deploys capital predominantly in venture-stage life sciences, digital health, and health technology. Its presence spans three continents, with offices and advisory relationships in the United States, France, Italy, and Singapore. The dual consultancy-investor model means SPRIM often enters cap tables early, sometimes before formal fundraising rounds. The investment strategy concentrates on companies navigating complex regulatory pathways — medical devices, diagnostics, and therapeutic platforms. SPRIM's advisory work for large pharmaceutical and medtech clients generates proprietary visibility into clinical validation pipelines, which feeds the investment decision process. Public records show the firm has backed companies including Biotia, a genomics and AI diagnostics startup, and participated in rounds for various digital therapeutic platforms (per Crunchbase, 2024). The firm invests directly, occasionally co-investing alongside European and Asian venture funds. Geographic deployment shows a heavier weighting toward European health-tech, reflecting the SPRIM group's strong French and Italian roots, with a growing allocation to US-based digital health. Team size and assets under management are not publicly disclosed. The investment committee operates out of the Singapore headquarters, with deal sourcing conducted through the group's advisory networks in Paris, Milan, and Boston. In October 2023, SPRIM participated in a funding round for a Singapore-based health-tech platform focused on chronic disease management (per DealStreetAsia, October 2023). The firm also maintains ties to the SPRIM Ventures structure, which occasionally acts as a co-investor on healthcare deals. There is no known philanthropic foundation or club-membership affiliation publicly tied to the entity. SPRIM's architecture is unusual: an investment firm embedded inside a consultancy that itself advises the healthcare industry's largest incumbents. This creates a flywheel where advisory fees fund operational infrastructure, and advisory relationships surface deal flow. The structure avoids the fundraising pressure of a pure-play venture firm while offering portfolio companies access to regulatory and clinical trial expertise that a typical financial investor cannot provide. Governance and succession details remain private, as do the identities of the ultimate beneficial owners behind the SPRIM group.